60 likes | 68 Views
Renal Denervation Market Report, published by Allied Market Research, forecasts that the global market was valued at $197 million in 2015, and is expected to reach $3,153 million by 2022, supported by a CAGR of 48.5% during the forecast period 2014 - 2022. Symplicity Renal Denervation System is estimated to continue generating highest revenue throughout the forecast period, owing to growing number of product approvals across the globe. Europe held the leading position in the global market in 2015, and is expected to maintain its lead in the future.<br><br>On the basis of product type, the Symplicity Renal Denervation System segment accounted for the largest share, while Vessix Renal Denervation System is projected to grow at the fastest rate. Radiofrequency segment dominated the overall renal denervation market. Utrasound is poised to grow at the highest CAGR of 56.4% during the analysis period. Europe was the leading geographic market in 2015, and it is projected to lead for the next few years. Asia-Pacific is projected to grow at the highest CAGR of 50.6%.<br>
E N D
Renal Denervation Market Report, published by Allied Market Research, forecasts that the global market was valued at $197 million in 2015, and is expected to reach $3,153 million by 2022, supported by a CAGR of 48.5% during the forecast period 2014 - 2022. Symplicity Renal Denervation System is estimated to continue generating highest revenue throughout the forecast period, owing to growing number of product approvals across the globe. Europe held the leading position in the global market in 2015, and is expected to maintain its lead in the future. Download Sample PDF Brochure at: https://www.alliedmarketresearch.com/request-sample/522 Renal Denervation Market
According to the analysis carried out for each segment, the Symplicity Renal Denervation System accounted for the largest market share in 2015. Symplicity is the major and most frequently used product of the renal denervation market. According to the CIRSE Member Survey (2013), Symplicity is used by approximately 78% of the European hospitals. This system is generally preferred as it delivers low level of RF energy and thus reduces the potential risks associated with high levels of RF radiation on body tissues. Above all, the device provides a minimally invasive method to treat excessive hypertension. In addition, the Vessix Renal Denervation System is expected to have the highest growth rate as it uses a full-color graphic user interface that increases the accuracy and operation of the device. This feature enables the Vessix system to be a preferred system by physicians as well as patients. Renal Denervation Market Segment Review:
On the basis of product type, the Symplicity Renal Denervation System segment accounted for the largest share, while Vessix Renal Denervation System is projected to grow at the fastest rate. • Radiofrequency segment dominated the overall renal denervation market. • Utrasound is poised to grow at the highest CAGR of 56.4% during the analysis period. • Europe was the leading geographic market in 2015, and it is projected to lead for the next few years. • Asia-Pacific is projected to grow at the highest CAGR of 50.6%. Key findings of Renal Denervation Market:
Renal Denervation Market by Product (Symplicity, EnligHTN, Vessix, Paradise and Iberis) and by Technology (Radiofrequency, Ultrasound and Micro-Infusion) - Global Opportunity Analysis and Industry Forecast, 2014-2022 Renal Denervation Market